Ocular Therapeutix, Inc. (OCUL)
8.73
+0.26
(+3.07%)
USD |
NASDAQ |
Jun 10, 16:00
8.73
0.00 (0.00%)
After-Hours: 20:00
Ocular Therapeutix SG&A Expense (Quarterly) : 36.58M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 36.58M |
| December 31, 2025 | 30.62M |
| September 30, 2025 | 29.11M |
| June 30, 2025 | 28.08M |
| March 31, 2025 | 30.50M |
| December 31, 2024 | 25.44M |
| September 30, 2024 | 22.81M |
| June 30, 2024 | 29.66M |
| March 31, 2024 | 24.33M |
| December 31, 2023 | 17.27M |
| September 30, 2023 | 17.90M |
| June 30, 2023 | 19.36M |
| March 31, 2023 | 19.96M |
| December 31, 2022 | 18.88M |
| September 30, 2022 | 18.72M |
| June 30, 2022 | 17.93M |
| March 31, 2022 | 16.62M |
| December 31, 2021 | 16.67M |
| September 30, 2021 | 17.65M |
| June 30, 2021 | 16.99M |
| March 31, 2021 | 15.75M |
| December 31, 2020 | 13.39M |
| September 30, 2020 | 12.48M |
| June 30, 2020 | 11.30M |
| March 31, 2020 | 12.31M |
| Date | Value |
|---|---|
| December 31, 2019 | 12.69M |
| September 30, 2019 | 12.93M |
| June 30, 2019 | 12.28M |
| March 31, 2019 | 8.705M |
| December 31, 2018 | 7.412M |
| September 30, 2018 | 5.514M |
| June 30, 2018 | 5.314M |
| March 31, 2018 | 5.488M |
| December 31, 2017 | 5.182M |
| September 30, 2017 | 7.468M |
| June 30, 2017 | 10.56M |
| March 31, 2017 | 9.303M |
| December 31, 2016 | 5.528M |
| September 30, 2016 | 3.917M |
| June 30, 2016 | 4.465M |
| March 31, 2016 | 3.795M |
| December 31, 2015 | 3.733M |
| September 30, 2015 | 3.249M |
| June 30, 2015 | 3.271M |
| March 31, 2015 | 2.764M |
| December 31, 2014 | 2.874M |
| September 30, 2014 | 2.405M |
| June 30, 2014 | 1.731M |
| March 31, 2014 | 1.885M |
| June 30, 2013 | 0.585M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| EyePoint, Inc. | 15.25M |
| LENZ Therapeutics, Inc. | 44.96M |
| Merck & Co., Inc. | 2.70B |
| Zevra Therapeutics, Inc. | 20.78M |
| Bristol Myers Squibb Co. | 1.617B |